Leerink Bullish on Bristol-Myers Squibb Company (BMY) Amid Ample Pipeline Optionality in 2026

On January 13, 2026, Leerink raised its terms people connected Bristol-Myers Squibb Company (NYSE:BMY) from $54.00 to $60.00, portion reiterating an ‘Outperform’ rating. Highlighting ample pipeline optionality successful 2026, the steadfast noted 12 registration information readouts crossed 8 assets. Most of these assets correspond imaginable caller launches and are presently importantly discounted by the market. With this backdrop, the steadfast expects beardown upside potential, particularly if cardinal trials present affirmative results.

The erstwhile day, successful enactment with Leerink’s affirmative outlook, Bristol-Myers Squibb Company (NYSE:BMY) reported affirmative topline results from SCOUT-HCM, a Phase 3 proceedings evaluating Camzyos (mavacamten) successful adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Meeting its superior endpoint, the proceedings importantly reduced Valsalva near ventricular outflow tract (LVOT) gradient astatine Week 28 compared to placebo. At the aforesaid time, secondary endpoints were besides met. Moreover, information was ensured among big patients, with nary caller signals observed. Looking ahead, absorption sees Camzyos becoming the archetypal cardiac myosin inhibitor for teen patients.

Bristol-Myers Squibb Company (NYSE:BMY) focuses connected discovering, developing, manufacturing, and selling biopharmaceuticals, including tiny molecules, biologics, and CAR-T therapies.

While we admit the imaginable of BMY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 7 Best Rising Tech Stocks to Buy Now and 12 Best Multibagger Stocks to Buy Heading into 2026.

Disclosure: None.